ERES East Resources Acquisition Company

Fast Growing Mid-Tier Pharmaceutical Company Signs Agreement with eResearchTechnology for Cardiac Safety Monitoring and Information Distribution Services Award Totals Approximately $1.2 Million and Includes Digital Collection, Interpretation, and Distribution of Cardiac Safety Data PHILADELPHIA, Dec. 22 /PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (eRT), , a leading provider of centralized electrocardiographic (ECG) collection and interpretation services, announced today that it has received an agreement for approximately $1.2 million in cardiac safety monitoring and services from a fast growing mid-tier pharmaceutical for one of its drug candidates in late phase development. The agreement covers a Phase III study that will be conducted at 60 research sites in the U.S. eRT will provide comprehensive site support and 60 units of 12-lead ECG recording equipment, which is designed to facilitate the collection of cardiac safety data that are subsequently provided to eRT for analysis. eRT will manage collection, measurement, interpretation, review, and distribution of cardiac safety data through its EXPeRT workflow enabled data handling technology, the first solution in production that was designed explicitly to meet emerging international regulatory guidance and technical standards. In addition, the agreement includes a subscription to eRT's Digital ECG Community, which delivers timely cardiac safety data feedback at the trial, center, dosing group, and patient level, along with related metrics, such as trial enrollment, as well as the ability to organize and publish a variety of study-specific information and the ability to link data points in reports direct to digital ECG waveforms. "This agreement represents the fourth significant study for this compound that has been awarded to eRT in the past two months," said Scott Grisanti, senior vice president of business development and chief marketing officer at eRT. "Scientific and technical consistency of cardiac safety evaluation services across an entire drug development program is growing in importance. This trend encourages the sponsor to evaluate an ECG core laboratory's capacity and throughput capabilities in addition to these other important areas." Based in Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com/) is a provider of technology and services to the pharmaceutical, biotechnology and medical device industries on a global basis. The company is a market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development. The company is also a leader in providing technology and services to streamline the clinical trials process by enabling its customers to automate the collection, analysis, and distribution of clinical data in all phases of clinical development. Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues in the sponsoring client. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the company's financial results can be found in the company's Reports on Forms 10-K and 10-Q filed with the Securities and Exchange Commission. DATASOURCE: eResearchTechnology, Inc. CONTACT: Joan Sterlacci, eResearchTechnology, Inc., +1-908-203-6473, or Matt Hayden, Hayden Communications, +1-760-487-1137, for eResearchTechnology Web site: http://www.ert.com/

Copyright